A global leader in orphan oncology

September, 2014

Judith Greciet - CEO Nicolas Fellmann - CFO

2

Looking-Forward Statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo SA and its business. Such statements involve certain know and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (http://www.amf-france.org) or on Onxeo's website (http://www.onxeo.com).

3

Business overview

Established in 1997 in France, listed on Euronext Paris in 2005

Develops innovative treatments addressing significant unmet needs in Orphan/Oncology diseases

Two advanced clinical programs and two supportive care registered/marketed products

Cash FY13: €11.3 million

Strong expertise and innovation

50 employees (70% R&D) with full-range of expertise from preclinical to registration & business development

Two technological platforms (Lauriad® and Transdrug™)

Fully proven expertise with two successful NDAs/ MAs

Extensive IP portfolio

Highly experienced management team and a highly skilled international Board of Directors

BioAlliance Pharma, a French Biotech company…

4

With a clear growth strategy Build on a leader in orphan oncology field

PRODUCT DISCOVERY PRECLINICAL PH1 PH2 PH3 REGISTRATION MARKET

Livatag® Primary Liver Cancer

Validive® Oral Mucositis

AMEP®/Synfoldin Metastatic Melanoma

And accelerate growth with strategic corporate development transactions

Lean on our advanced product pipeline development

Breakthrough highly innovative products in diseases with strong unmet medical need and large sales potential (up to €800M)

5

BioAlliance Pharma & Topotarget, the perfect fit for a merger

Business overview BioAlliance Pharma

Established in 1997 in France, listed on Euronext Paris in 2005 ( BIO )

50 employees w/ expertise from preclinical to registration, IP & BD

Develops innovative treatments addressing significant unmet needs in Orphan/Oncology diseases

Two advanced clinical programs and two specialty products registered/marketed products

Average 3 months: market cap 170 M€, liquidity 1.8 M€/day

Business overview Topotarget

Established in 2000, listed on NASDAQ OMX Copenhagen ( TOPO)

12 employees

Focused on late-stage programs in orphan oncology

Beleodaq®, lead product registered in the U.S., strong partnership with US pharma Spectrum (SPPI).

Average 3 months: market cap 75 M€, liquidity 0.4 M€/day

6

… to create a leader in orphan oncology, based in Europe

Supported by a highly complementary pipeline of late-stage products with several significant value-creating events in both the short and medium term

Benefiting from operational efficiencies: combined knowledge-sharing, and a diversified revenue stream driving growth

Resulting in a broadened shareholders base with increased market capitalization and increased attractiveness to investors

Under the leadership of an experienced management team and supervised by a highly skilled international Board of Directors with proven track records

Dedicated to the development of innovative therapies for orphan oncology diseases with increased value creation for shareholders

7

Onxeo, our vision, our mission

Driven by a strong vision:

“To be a global leader and pioneer in oncology, with a focus on orphan diseases, to make the difference”

Dedicated to its mission:

“We are determined to develop innovative medicines to provide patients with hope and improve their lives“

8

Onxeo corporate profile & key strengths

Headquartered in Paris, Listed on Euronext Paris and NASDAQ OMX Copenhagen

– Shareholders approvals of the merger: 27 & 30 June, 2014, Merger completion: July 22, 2014

– Name change August 1st , Onxeo shares will be listed from August 6th on both markets

Approximately 60 employees, strong expertise from preclinical to registration, BD & IP

Dedicated to orphan oncology diseases, for diseases with high unmet needs

– 3 technological platforms/assets and multiple potential applications

– 3 programs in advanced clinical development, synergic while independent

– 3 products approved Europe and/or US

International partnerships

– Spectrum for Beleodaq® (North America, India)

– Innocutis for Sitavig® (USA)

– Sosei for Loramyc® in Japan

– …

9

Experienced Management Team and Board of Directors

Highly skilled Franco-Danish management team

CEO: Judith Greciet, 15 years in strategy and operations

Onxeo Executive committee will be enlarged with Topotarget key expertise

Track record of bringing products through the FDA and EMA approvals process (Belinostat, Loramyc®/Oravig®, Sitavig®, ..)

International Board of Directors reflecting the spirit of the company

International Board of Directors chaired by P. Langlois (former CFO of Aventis SA), with the addition of Bo J. Hansen (Chairman of SOBI) from Topotarget

Shareholders represented by Financière de la Montagne (N. Trebouta) & Per Samuelsson (Healthcap)

Experienced individuals highly skilled in strategy, product development, pharma and biotech environment, external growth, M&A and financing

10

Growth strategy: Build on a leader in orphan oncology

PRODUCT PH PH2 PH3 REGISTRATION LAUNCH MILESTONES

Beleodaq® ( PTCL 2nd L)

US registered July 2014

Combo BelCHOP (PTCL 1st Line)

Livatag® (HCC 2nd Line) Ph 3 Read-out end 2016

Validive® (Oral Mucositis) Ph 2 preliminary data Q4 2014

NCI sponsored Studies Solid Tumors & Lymphomas In patients with Hepatic Dysfct

Onxeo advanced product pipeline Belinostat: two to four additional indications anticipated in hematology/solid tumors with a sales potential > €250M worldwide

Livatag®/ Validive®: extended indications to enlarge market value potential

12

BELEODAQ® Advanced HDACi with large potential

Beleodaq® (Belinostat) , HDAC inhibitor, epigenetic compound

Only pan HDACi with oral and IV formulations

Increase in acetylation of histone and non histone proteins: induces cell cycle arrest, apoptosis and decrease in tumor proliferation

Effective as monotherapy and combination therapy

Large clinical development already performed

Indications in hematology and solid tumors

More than 1200 patients treated through phase I - III clinical trials

IP and regulatory status

Long-term IP, until 2027 in the U.S.

NDA granted by FDA on July 3, 2014 in second line PTCL

Orphan status granted in US and Europe

13

BELEODAQ® Accelerated Approval granted from FDA in PTCL

Peripheral T-cell lymphoma – PTCL

A subtype of non-Hodgkin’s lymphoma (NHL) which affects T-cells

Estimated global incidence of 12,000/year (10-15% NHL)

Only conditionally approved products available in the US in second line

Beleodaq® (Belinostat) pivotal phase II in PTCL 2nd Line

Positive trial (BELIEF study) showing efficacy and favorable safety profile

– N =129, open label study in patients with relapsed or refractory PTCL

– 25% Overall Response rate - 8.3 month median duration of response

– Low incidence of myelosuppression, well tolerated in patients with low platelets

Angioimmunoblastic T Cell lymphoma (AITL) - subgroup of BELIEF study (17%):

– 45% Overall Response rate - 8.3 month median duration of response

Phase III randomized confirmatory trial: first line in combo with CHOP

First line treatment in PTCL: Beleodaq® + CHOP versus CHOP

On going: Phase I combination Belinostat + CHOP in naive PTCL patients

14

LIVATAG® to overcome resistance in HCC

Doxorubicin nanoformulated

Proprietary Transdrug™ platform

Design to bypass tumor cell resistance – Encoded by multidrug resistance (MDR) genes – Ions pair doxo/PIHCA preventing doxo – MDR interactions

Hepatocellular Carcinoma (HCC)

782.000 new cases & 746.000 deaths yearly

40 to 60% of patients are diagnosed at late stage, highly resistant

One approved drug: Sorafenib for advanced HCC

IP and regulatory status

Intellectual protection until 2032

Orphan status in both Europe and US, Fast track designation in US

Sales potential estimated up to 800m€

Mechanism of action of Livatag®

16

LIVATAG® “ReLive” Phase III trial to assess efficacy

400 patients study

Initiated in 2012, study extension in 2013

US: IND obtained in Dec 2013, implementation ongoing

Europe: Germany, Italy, Spain, Russia, Austria, Belgium, Bulgaria

+ 30% of patients enrolled

4th DSMB held in April 2014 with positive recommendation

Estimated timelines: LPI end 2015 / Preliminary results end 2016

Multicenter randomized controlled open label vs Best Standard of Care Efficacy (OS) and safety of Livatag® (20 and 30mg/m² - slow IV) vs BSC after

failure or intolerance to sorafenib

17

VALIDIVE® to prevent severe oral mucositis

Validive® innovative therapeutic new option

Mucoadhesive tablet (Lauriad®) delivering early and sustained concentration of clonidine directly in the mouth to preventing severe oral mucositis

α- 2 receptor inhibition with strong antiinflammatory properties

Oral mucositis

Inflammation and ulceration of oral mucosa induced by chemo-radio therapies

Highly frequent in H&N cancer patients > 80%

150.000 H&N cancer patient/year, leading to severe OM thus radiotherapy breaks or delays & increased hospitalization

No preventive treatment approved in solid cancer

IP and regulatory status

Orphan status in Europe, IP until 2029

Fast track designation allowing accelerated review by FDA

Sales potential estimated between 200 and 400m€

19

VALIDIVE® Phase II – Data expected by end 2014

Daily application for up 8 weeks with a 4-week follow up

185 patients enrolled by early May 2014 - LPI

Preliminary results expected in 4Q2014

Primary endpoint: % Efficacy of Validive® 50 μg and 100 μg vs placebo

International board of experts in place to advise on development

strategy and medical positioning of Validive® in oral mucositis

Multicenter, randomized, double-blind placebo-controlled, to assess

Validive® efficacy to prevent severe oral mucositis in H&N cancer patients

20

Non core product Sitavig®: A 2nd NDA Establishing our Know-How

Sitavig®

One single 50mg mucoadhesive tablet to treat recurrent labial herpes

International Licensing strategy with partners in the US, Brazil and Korea

Commercialization in the US since July 2014 by partner Innocutis, specialized in dermatology

Strong IP until 2029/2030 in major markets

21

Onxeo, a unique short and mid-term newsflow to drive value

Beleodaq®

Launch in the US by Spectrum Pharma 3Q 2014

Phase I combination Q2 2015

Validive® Phase II trial

Preliminary results 4Q 2014

Phase III trial H2 2015

Livatag® Phase III trial (recruitment ongoing)

Next DSMB 4Q 2014

End of recruitment (LPLV) 2Q 2016

22

Key financial highlights

Strengthened financial parameters Proforma financial information – June 30, 2014

Consolidated cash balance: 19.2 M€

Consolidated revenues H1: 13.9 M€

including 13.2 M€ in cash/equity milestones from US partner Spectrum (Approval for filing of Beleodaq® NDA – Feb. 2014)

H2 financial drivers 10 M€ shareholder’s loan from Financière de la Montagne (July 2014)

25 M$ milestone to be received from US partner Spectrum, triggered by the July NDA

approval of Beleodaq®

23

Key financial highlights

10,4% 4,3%

85,3%

Financière de la Montagne / Idinvest Partners HealthCap Funds / HBM Healthcare Others

Strengthened Capital Market Position Heightened international visibility

Dual listing in Paris and Copenhagen / Tickers Euronext & Nasdaq OMX: Onxeo

Increased critical mass

Market capitalization 200 M€ - Share price 6.37€ ( 09/09)

Liquidity Euronext 1 month 1.2 M€ - Paris Total shares: 31,482,333

Reinforced shareholders base with key long term shareholders

24

Onxeo, a leader and pioneer in orphan oncology… to make the difference

A winning player

Operating in an attractive market: orphan oncology

With a strong pipeline: 3 advanced development programs with multiple applications

Proven expertise with accomplished teams

Bright future for additional value creation

Significant short-term and mid-term catalysts

Heightened attractiveness for US and European-based investors

Dedicated to develop innovative medicines to provide patients with hope and improve their lives

49 Bld du Général Martial Valin

75015 Paris - France

Tél. +33 (0)1 45 58 76 00

Fax +33 (0)1 45 58 08 81

contact@onxeo.com

www.onxeo.com